Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.

de Brabander J, Duijvelaar E, Schippers JR, Smeele PJ, Peters-Sengers H, Duitman JW, Aman J, Bogaard HJ, van der Poll T, Bos LDJ, CounterCOVID Study Group

Open source

DOI: 10.1183/13993003.00780-2022
Published: 2022 Dec
Container: The European respiratory journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1183/13993003.00780-2022,
  title = {Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.},
  author = {de Brabander J and Duijvelaar E and Schippers JR and Smeele PJ and Peters-Sengers H and Duitman JW and Aman J and Bogaard HJ and van der Poll T and Bos LDJ and CounterCOVID Study Group},
  year = {2022},
  journal = {The European respiratory journal},
  doi = {10.1183/13993003.00780-2022},
  url = {https://doi.org/10.1183/13993003.00780-2022}
}

RIS

TY  - JOUR
TI  - Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.
AU  - de Brabander J
AU  - Duijvelaar E
AU  - Schippers JR
AU  - Smeele PJ
AU  - Peters-Sengers H
AU  - Duitman JW
AU  - Aman J
AU  - Bogaard HJ
AU  - van der Poll T
AU  - Bos LDJ
AU  - CounterCOVID Study Group
PY  - 2022
JO  - The European respiratory journal
DO  - 10.1183/13993003.00780-2022
UR  - https://doi.org/10.1183/13993003.00780-2022
ER  -

APA

J, D. B., E, D., JR, S., PJ, S., H, P., JW, D., J, A., HJ, B., T, V. D. P., LDJ, B., & Group, C. S. (2022). Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.. The European respiratory journal. https://doi.org/10.1183/13993003.00780-2022

Source records

pubmed · retrieved 2026-11-10T08:30:00.964Z